​

Funding Round

Series B - IO Biotech

Series B - IO Biotech

Investment Firm

Overview

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

Announced Date

Jan 13, 2021

Funding Type

Series B

Highlights

Location

Europe

Social

Investor Lead

HBM Healthcare Investments

HBM Healthcare Investments

HBM Healthcare Investments is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Participant Investors

12

Investor Name
Participant InvestorKurma Partners
Participant InvestorNovo Holdings
Participant InvestorIdinvest Partners
Participant InvestorSunstone Life Science Ventures
Participant InvestorVivo Capital

Round Details and Background

IO Biotech raised $154457623 on 2021-01-13 in Series B

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
May 12, 2020
Debt Financing - IO Biotech
3-8.7M
Oct 07, 2021
Series C - IO Biotech
1-undefined
Aug 07, 2023
Post-IPO Equity - IO Biotech
-undefined
Jan 05, 2016
Series A - IO Biotech
2-11.8M

Recent Activity

There is no recent news or activity for this profile.